NMN

≥98% HPLCCOA per batchCold-chain shippedIn-house synthesisResearch use only · not for human consumption

Price range: $39.99 through $109.99

Independently verified Tested by IRZC Laboratories Batch NHV26-B5499 · Purity 99.16 % HPLC · Issued 4 Aug 2026 · Cert COA-K8PR-MXGV-FVerify at IRZCVerifyScan to verify

A naturally occurring nucleotide and direct biosynthetic precursor to NAD+, extensively researched for its role in cellular energy metabolism, DNA repair, sirtuin activation, and anti-aging biology.

FormulaC11H15N2O8P
Mol. weight334.22 g/mol
FormLyophilised powder
3 People watching this product now!
SKU: PEP-079 Category:

Molecular & analytical data

Verified chemistry and third-party reference identifiers for this compound.

Amino acid sequenceNot a peptide; nucleotide structure: nicotinamide + ribose-5-phosphate
Molecular formulaC11H15N2O8P
Molecular weight334.22 g/mol
CAS number1094-61-7
PubChem CIDCID 14180 ↗
Purity standard≥98%
Half-lifeNot established in humans; NMN is rapidly metabolised to nicotinamide and incorporated into the tissue NAD+ pool rather than persisting in plasma
BioavailabilityOral: rapidly absorbed; peak plasma in ~1-2 hours; muscle uptake via Slc12a8 transporter
Origin / sourceNaturally occurring in all living cells; dietary sources include edamame, broccoli, avocado, tomatoes; commercial NMN is produced by enzymatic or fermentation synthesis
Year discovered1963 (structural identification); anti-aging research intensified 2013–present
NMN molecular structure
2D structure · source: PubChem

Reconstitution calculator

Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →

Concentration— mg/mL— mcg per unit
—Draw tounits on a U-100 syringe
—Volume / drawmL
—Complete drawsper vial

—

A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.

Quality & verification

Every batch is characterised before release and ships with documentation.

≥98%HPLC purity
334.22 g/molMolecular weight
MS + HPLCIdentity & purity assay
Third-party testedBatches are tested by IRZC Laboratories — independent HPLC + mass-spec confirms identity and purity against that product’s release specification.
Batch-matched COAA certificate of analysis is issued per batch and matched to your vial’s lot number.
Cold-chain fulfilmentLyophilised product is packed with insulated, temperature-controlled shipping.
Controlled synthesisProduced under documented, reproducible in-house processes with lot traceability.

Storage & handling

Keep the peptide stable from delivery through reconstitution.

1
On arrivalStore the sealed, lyophilised vial frozen at −20°C, protected from light and moisture.
2
ReconstitutionAdd bacteriostatic water down the vial wall; swirl gently — do not shake. Use the calculator above to plan volume.
3
After mixingRefrigerate the reconstituted solution at 2–8°C and use within the stability window below.
4
HandlingWork in a clean area, wipe the stopper with alcohol, and avoid repeated freeze–thaw cycles.
Manufacturer storage note

Store at room temperature in sealed container away from moisture and light. Hygroscopic — keep tightly closed.

Description

Nicotinamide mononucleotide (NMN, β-NMN) is a naturally occurring ribonucleotide that serves as a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for over 400 enzymatic reactions. NAD+ levels decline progressively with age, contributing to mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and increased metabolic disease risk — processes implicated in aging and age-related disorders. NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT) enzymes. The NAMPT-mediated salvage pathway, which produces NMN from nicotinamide, is a primary route of NAD+ biosynthesis in mammals. Animal studies have demonstrated that NMN supplementation restores NAD+ levels in aging tissues, improves insulin sensitivity, enhances mitochondrial biogenesis, activates sirtuins (SIRT1, SIRT3), and extends healthspan parameters. Human clinical trials have confirmed that NMN safely elevates blood NAD+ concentrations (optimal at 600 mg/day), with studies showing improvements in muscle insulin sensitivity in prediabetic women, reduced biological aging markers, and good tolerability at up to 900 mg/day.

Certificates of Analysis

Certificates of Analysis

Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.

Batch #IssuedPurityCertificate
NHV26-B5499
COA-K8PR-MXGV-F
04 Aug 202699.16 % HPLCVerify at IRZC ↗

“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.

Research & Literature
Reported in research literature — not usage guidance.

The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.

Mechanism of action

Converted to NAD+ by NMNAT enzymes; NAD+ activates sirtuins (SIRT1-7) for epigenetic regulation and DNA repair; NAD+ is cofactor for PARPs (DNA repair), CD38/CD157 (immune signaling), and over 400 oxidoreductases; restores mitochondrial function; activates AMPK pathway.

Primary uses / indications

Age-related NAD+ decline, metabolic syndrome, insulin resistance, cognitive aging, mitochondrial dysfunction, DNA repair support, longevity research, energy metabolism

Typical dosage (reported)

250–900 mg/day oral (clinical trials); most human studies use 250–500 mg/day; higher doses up to 2000 mg/day in some protocols

Cycle duration (reported)

Continuous supplementation or 3-month cycles; no established maximum duration

Administration route

Oral (capsule/powder), Subcutaneous injection (less common)

Side effects (reported)

Generally well tolerated. Mild GI effects (nausea, diarrhea) at high doses. Potential for excessive NAD+ metabolite production. Long-term safety data beyond 12 months limited.

Contraindications

Active cancer (NAD+ promotes cellular energy for all cells including cancer); pregnancy/breastfeeding (insufficient safety data)

Drug interactions

Potential interactions with PARP inhibitors (olaparib, niraparib) — mechanistic overlap; additive effects with resveratrol, metformin (AMPK pathway); caution with DNA-damaging chemotherapy agents

Reviews (0)
0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “NMN”

Your email address will not be published. Required fields are marked *

You have to be logged in to be able to add photos to your review.

Specifications

Identity

Full name / brand namesNMN / Nicotinamide Mononucleotide / β-Nicotinamide Mononucleotide
CategoryAnti-Aging & Longevity
SubcategoryNAD+ Precursor
Origin / sourceNaturally occurring in all living cells; dietary sources include edamame, broccoli, avocado, tomatoes; commercial NMN is produced by enzymatic or fermentation synthesis
Year discovered1963 (structural identification); anti-aging research intensified 2013–present

Chemistry

Amino acid sequenceNot a peptide; nucleotide structure: nicotinamide + ribose-5-phosphate
Molecular formulaC11H15N2O8P
Molecular weight334.22 g/mol
CAS number1094-61-7
PubChem CIDCID 14180 ↗
Purity standard≥98%

Pharmacokinetics

Half-lifeNot established in humans; NMN is rapidly metabolised to nicotinamide and incorporated into the tissue NAD+ pool rather than persisting in plasma
BioavailabilityOral: rapidly absorbed; peak plasma in ~1-2 hours; muscle uptake via Slc12a8 transporter

Regulatory & research status

FDA statusNot FDA-approved as a drug. In November 2022 FDA concluded that NMN was excluded from the dietary-supplement definition under the drug-preclusion provision of the FD&C Act; in September 2025 FDA reversed that position, concluding that NMN is not excluded and may lawfully be used in dietary supplements.
Prescription requiredNot required (dietary supplement in US)
Research statusActive human clinical trials; multiple completed phase 1/2 studies; extensive preclinical data
Clinical trialsNCT04823260 (NMN in healthy middle-aged adults); NCT04228640 (NMN safety and anti-aging); NCT03151239 (NMN in postmenopausal women)

References

Yoshino J et al., "Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice", Cell Metabolism, 2011, DOI: 10.1016/j.cmet.2011.08.014; Igarashi M et al., "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels in healthy subjects", NPJ Aging and Mechanisms of Disease, 2022, DOI: 10.1038/s41514-022-00084-z; Yoshino M et al., "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women", Science, 2021, DOI: 10.1126/science.abe9985

Frequently asked questions

What is NMN?
A naturally occurring nucleotide and direct biosynthetic precursor to NAD+, extensively researched for its role in cellular energy metabolism, DNA repair, sirtuin activation, and anti-aging biology.
How does NMN work?
Reported in the research literature: Converted to NAD+ by NMNAT enzymes; NAD+ activates sirtuins (SIRT1-7) for epigenetic regulation and DNA repair; NAD+ is cofactor for PARPs (DNA repair), CD38/CD157 (immune signaling), and over 400 oxidoreductases; restores mitochondrial function; activates AMPK pathway.
What NMN dosage is used in research?
For laboratory research reference only, not usage guidance: 250–900 mg/day oral (clinical trials); most human studies use 250–500 mg/day; higher doses up to 2000 mg/day in some protocols
What is the half-life of NMN?
The reported biological half-life of NMN is approximately Not established in humans; NMN is rapidly metabolised to nicotinamide and incorporated into the tissue NAD+ pool rather than persisting in plasma.
How should NMN be stored and reconstituted?
NHOV ships NMN as a lyophilised powder. Store unopened vials at −20 °C. Reconstitute with bacteriostatic water; once reconstituted, refrigerate at 2–8 °C, protect from light, and use within the bacteriostatic-water shelf window. Use the NHOV reconstitution calculator to find the exact volume for your target concentration.
What purity is NHOV's NMN?
NHOV NMN is released against a specification of ≥98%, verified by HPLC with mass-spectrometry identity confirmation, and ships with a batch-specific Certificate of Analysis (COA) matched to the vial's lot number.
Is NMN approved for human use?
No. NMN is sold strictly for laboratory and scientific research use only. It is not for human or veterinary consumption and is not approved as a drug.